STOCK TITAN

Redmile updates 9.9% Shattuck Labs (STTK) stake after July trades

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments II, L.P. updated their ownership report for Shattuck Labs, Inc. common stock. They may be deemed to beneficially own 10,019,421 shares, representing 9.9% of the class, with shared voting and dispositive power over all of these shares. Redmile Biopharma Investments II, L.P. is reported with 8,125,342 shares, or 8.1% of the class.

The position as of July 17, 2026 comprises 5,233,076 shares of common stock (including 3,338,997 shares held directly by RBI II) plus 4,786,345 shares issuable upon exercise of pre-funded warrants, the maximum permitted under a 9.99% Beneficial Ownership Limitation. The Redmile funds hold pre-funded warrants for up to 10,943,951 shares, including 5,647,258 underlying shares at RBI II, and 146,086 shares subject to stock options exercisable within 60 days that are held by a former director as nominee for Redmile. Between July 10 and July 17, 2026, the group executed multiple open market sales and on July 17 used approximately $1,000,000 of working capital to purchase 143,808 shares at a weighted average price of about $7.46 per share.

Positive

  • None.

Negative

  • None.
Beneficial ownership (Redmile/Green) 10,019,421 shares (9.9%) Common stock beneficially owned as of July 17, 2026
Beneficial ownership (RBI II) 8,125,342 shares (8.1%) Common stock beneficially owned by Redmile Biopharma Investments II, L.P.
Open-market purchase 143,808 shares at ~$7.46 per share Shares bought on July 17, 2026 using about $1,000,000 of working capital
Shares held by Redmile funds 5,233,076 shares Common stock directly held by Redmile funds, including RBI II
Shares from pre-funded warrants (counted) 4,786,345 shares Maximum issuable under 9.99% Beneficial Ownership Limitation included in ownership
Total warrant underlying shares 10,943,951 shares Common shares underlying all pre-funded warrants held by Redmile funds
Stock options included 146,086 shares Shares subject to options exercisable within 60 days, held by a former director as nominee
Shares outstanding baseline 95,508,165 shares Common stock outstanding after underwritten offering used for percentage calculations
Beneficial Ownership Limitation regulatory
"which is the maximum number of shares of Common Stock that could be issued upon exercise of the Pre-Funded Warrants under the 9.99% beneficial ownership limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
pre-funded warrants financial
"shares of Common Stock issuable to the Redmile Funds, including RBI II, upon exercise of certain pre-funded warrants to purchase Common Stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
open market transactions financial
"The participating Redmile Funds purchased the shares in open market transactions at a price of approximately $7.46 per share"
Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.
working capital financial
"utilized their working capital in an aggregate amount of approximately $1,000,000 to acquire 143,808 shares"
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.
underwritten offering financial
"shares of Common Stock outstanding immediately after the Underwritten Offering (including the exercise of the underwriters' option to purchase additional shares of Common Stock)"
An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.
beneficially owned regulatory
"The aggregate amount of shares of Common Stock that may be deemed beneficially owned by the Reporting Persons as of July 17, 2026"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Redmile Group report in Shattuck Labs (STTK)?

Redmile Group and Jeremy C. Green may be deemed to beneficially own 10,019,421 Shattuck Labs shares, representing 9.9% of the common stock. This includes both shares held outright and shares issuable upon exercise of certain pre-funded warrants and stock options.

What is Redmile Biopharma Investments II, L.P.’s ownership in STTK?

Redmile Biopharma Investments II, L.P. is reported with 8,125,342 Shattuck Labs shares, or 8.1% of the common stock. This includes 3,338,997 shares held directly and additional shares issuable upon exercise of pre-funded warrants subject to a 9.99% limitation.

What July 2026 trades in STTK did Redmile disclose?

From July 10 to July 17, 2026, Redmile reported several open market sales of Shattuck Labs common stock and, on July 17, a purchase of 143,808 shares for about $1,000,000 at a weighted-average price of roughly $7.46 per share.

How many Shattuck Labs shares are tied to Redmile’s pre-funded warrants?

Redmile funds hold pre-funded warrants exercisable for up to 10,943,951 Shattuck Labs shares, including 5,647,258 underlying shares at RBI II. Due to a 9.99% Beneficial Ownership Limitation, only 4,786,345 issuable shares are counted in the reported beneficial ownership.

What is the 9.99% Beneficial Ownership Limitation mentioned for STTK?

The 9.99% Beneficial Ownership Limitation caps how many Shattuck Labs shares Redmile’s pre-funded warrants can be exercised into at any time. As a result, only 4,786,345 of the 10,943,951 underlying warrant shares are included in the beneficial ownership calculation.





82024L103

(CUSIP Number)
Redmile Group, LLC
Attn: Josh Garcia, 900 Larkspur Landing Circle, Suite 270
Larkspur, CA, 94939
(415) 489-9980

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
07/15/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) The source of funds was working capital of certain private investment funds managed by Redmile Group, LLC (the "Redmile Funds"), including Redmile Biopharma Investments II, L.P. ("RBI II"). (2) The information in Item 5(a) relating to the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as of July 17, 2026 and the calculation of the beneficial ownership percentage of such class of securities is incorporated by reference herein.


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) The source of funds was working capital of the Redmile Funds, including RBI II. (2) The information in Item 5(a) relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy Green as of July 17, 2026 and the calculation of the beneficial ownership percentage of such class of securities is incorporated by reference herein.


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) The information in Item 5(a) relating to the shares of Common Stock that are or may be deemed beneficially owned by RBI II as of July 17, 2026 and the calculation of the beneficial ownership percentage of such class of securities is incorporated by reference herein.


SCHEDULE 13D


Redmile Group, LLC
Signature:/s/ Jeremy C. Green
Name/Title:Managing Member
Date:07/17/2026
Jeremy C. Green
Signature:/s/ Jeremy C. Green
Name/Title:Jeremy C. Green
Date:07/17/2026
Redmile Biopharma Investments II, L.P.
Signature:/s/ Jeremy C. Green
Name/Title:Managing Member of Redmile Biopharma Investments II (GP), LLC, general partner of Redmile Biopharma Investments II, L.P.
Date:07/17/2026